Treating prehypertension: A review of the evidence

Current Hypertension Reports

Volumn 10, Issue 4, 2008, Pages 326-329

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 52449085587     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0060-8     Document Type: Review

References (18)

1. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
2. Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
3. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
4. Mancia G, De BG, Dominiczak A, et al.: 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25:1751-1762.
5. Qureshi AI, Suri MF, Kirmani JF, et al.: Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005, 36:1859-1863.
6. Kshirsagar AV, Carpenter M, Bang H, et al.: Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006, 119:133-141.
7. Sipahi I, Tuzcu EM, Schoenhagen P, et al.: Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary, atherosclerosis. J Am Coll Cardiol 2006, 48:833-838.
8. Nguyen TT, Wang JJ, Wong TY: Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 2007, 30:2708-2715.
9. Syamala S, Li J, Shankar A: Association between serum uric acid and prehypertension among US adults. J Hypertens 2007, 25:1583-1589.
10. Kokkinos P, Pittaras A, Narayan P, et al.: Exercise capacity and blood pressure associations with left ventricular mass in prehypertensive individuals. Hypertension 2007, 49:55-61.
11. Erdogan D, Yildirim I, Ciftci O, et al.: Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 2007, 115:593-599.
12. Ninomiya T, Kubo M, Doi Y, et al.: Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study. J Am Soc Nephrol 2007, 18:2135-2142.
13. Hansen TW, Staessen JA, Zhang H, et al.: Cardiovascular outcome in relation to progression to hypertension in the Copenhagen MONICA cohort. Am J Hypertens 2007, 20:483-491.
14. Freis ED, Ragan D, Pillsbury H 3rd, Mathews M: Alteration of the course of hypertension in the spontaneously hypertensive rat. Circ Res 1972, 31:1-7.
15. Harrap SB, Van der Merwe WM, Griffin SA, et al.: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990, 16:603-614.
16. Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685-1697.
17. Skov K, Eiskjaer H, Hansen HE, et al.: Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007, 50:89-95.
18. Brett AS: Ethical issues in risk factor intervention. Am J Med 1984, 76:557-561.